<DOC>
	<DOCNO>NCT00468312</DOCNO>
	<brief_summary>This study design assess effectiveness mometasone furoate nasal spray ( MFNS ) daily compare placebo subject seasonal allergic rhinitis ( SAR ) reduce total symptom score .</brief_summary>
	<brief_title>Placebo-Controlled Study Mometasone Furoate Nasal Spray ( MFNS ) 200 mcg QD Treatment Seasonal Allergic Rhinitis ( Study P05106 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<criteria>Must 12 year age old , either sex race . Must least 2year documented history SAR exacerbate study season . Must positive skinprick test response appropriate seasonal allergen Screening ( Visit 1 ) . IgEmediated hypersensitivity appropriate seasonal allergen ( ie , prevail tree and/or grass ) must document positive response skin prick test wheal diameter least 3 mm large diluent control 20 minute . Must clinically symptomatic Screening Visit . Must clinically symptomatic Baseline Visit . Must general good health confirm routine clinical laboratory test ECG result . Clinical laboratory test ( CBC , blood chemistry , urinalysis ) must within normal limit clinically acceptable investigator sponsor . Must free clinically significant disease , SAR , would interfere study evaluation . A subject and/or parent/guardian must willing give write informed consent must able adhere dose visit schedule meet study requirement . A female subject childbearing potential must negative serum pregnancy test ( HCG ) Screening . Nonsterile premenopausal female subject must use medically acceptable method birth control , ie , double barrier method , oral contraceptive , hormonal implant , depot injectable prior Screening study . A history anaphylaxis and/or severe local reaction ( ) skin test . A subject asthma require chronic use inhale systemic corticosteroid . Current history frequent , clinically significant sinusitis chronic purulent postnasal drip . A subject rhinitis medicamentosa . A history allergies two class medication allergic tolerate nasal spray . A subject upper respiratory tract sinus infection require antibiotic therapy without least 14day washout prior Screening Visit , viral upper respiratory infection within 7 day Screening Visit . A subject nasal structural abnormality , include large nasal polyp mark septal deviation , significantly interfere nasal air flow . A subject , opinion investigator , dependent nasal , oral , ocular decongestant , nasal topical antihistamine , nasal steroid . Use drug investigational protocol 30 day Screening Visit . A subject immunotherapy ( desensitization therapy ) , unless subject regular maintenance schedule prior Screening Visit stay schedule remainder study . A subject may receive desensitization treatment within 24 hour visit . Pregnant nursing female . Family member investigation study staff . Current evidence clinically significant hematopoietic , cardiovascular , hepatic , renal , neurologic , psychiatric , autoimmune disease , disease precludes subject 's participation study . Particular attention give exclude subject condition would currently interfere absorption , distribution , metabolism , excretion study drug interfere subject 's ability complete reliably complete diary . Significant medical condition ( ) , judgment investigator , might interfere study require treatment . A subject whose ability provide inform consent compromise . A subject history noncompliance medication treatment protocol .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>